AdΔ24 and the p53-expressing variant AdΔ24-p53 achieve potent anti-tumor activity in glioma when combined with radiotherapy

Journal of Gene Medicine

Volumn 9, Issue 12, 2007, Pages 1046-1056

  Idema, Sander ^a   Lamfers, Martine L M ^a,b   van Beusechem, Victor W ^a   Noske, David P ^a   Heukelom, Stan ^a   Moeniralm, Sharif ^a   Gerritsen, Winald R ^a   Vandertop, W Peter ^a   Dirven, Clemens M F ^a,b  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Adenovirus; Glioma; Oncolysis; Radiotherapy; Virotherapy

Indexed keywords

CONDITIONALLY REPLICATING ADENOVIRUS; PROTEIN P53;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER RADIOTHERAPY; CANCER SURVIVAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; GLIOMA; IN VITRO STUDY; IN VIVO STUDY; MOUSE; MULTIMODALITY CANCER THERAPY; NONHUMAN; ONCOLYTIC VIROTHERAPY; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RADIOSENSITIVITY; SURVIVAL TIME; TUMOR REGRESSION; VIRUS REPLICATION; ADENOVIRUS; ANIMAL; BRAIN TUMOR; GENE THERAPY; GENETICS; HUMAN; NUDE MOUSE; PHOSPHORYLATION; TUMOR CELL LINE;

ADENOVIRIDAE; ANIMALIA; MUS;

ADENOVIRIDAE; ANIMALS; BRAIN NEOPLASMS; CELL LINE, TUMOR; FEMALE; GENE THERAPY; GLIOMA; HUMANS; MICE; MICE, NUDE; PHOSPHORYLATION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 37348998988     PISSN: 1099498X     EISSN: 15212254     Source Type: Journal    
DOI: 10.1002/jgm.1113     Document Type: Article

References (42)

1. Kirn D, Martuza RL, Zwiebel J. Replication-selective virotherapy for cancer: biological principles, risk management and future directions. Nat Med 2001; 7: 781-787.
2. Worgall S, Wolff G, Falck-Pedersen E, et al. Innate immune mechanisms dominate elimination of adenoviral vectors following in vivo administration. Hum Gene Ther 1997; 8: 37-44.
3. Fueyo J, Gomez-Manzano C, Alemany R, et al. A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo. Oncogene 2000; 19: 2-12.
4. Ueki K, Ono Y, Henson JW, et al. CDKN2/p16 or RB alterations occur in the majority of ghoblastomas and are inversely correlated. Cancer Res 1996; 56: 150-153.
5. Collins VP. Brain tumours: classification and genes. J Neurol Neurosurg Psychiatty 2004; 75(Suppl 2): ii2-11.
6. Dix BR, O'Carroll SJ, Myers CJ, et al. Efficient induction of cell death by adenoviruses requires binding of E1B55k and p53. Cancer Res 2000; 60: 2666-2672.
7. Hall AR, Dix BR, O'Carroll SJ, et al. p53-dependent cell death/ apoptosis is required for a productive adenovirus infection. Nat Med 1998; 4: 1068-1072.
8. van Beusechem VW, van den Doel PB, Grill J, et al. Conditionally replicative adenovirus expressing p53 exhibits enhanced oncolytic potency. Cancer Res 2002. 62: 6165-6171.
9. Geoerger B, Vassal G, Opolon P, et al. Oncolytic activity of p53-expressing conditionally replicative adenovirus AdDelta24-p53 against human malignant glioma. Cancer Res 2004; 64: 5753-5759.
10. Sauthoff H, Pipiya T, Heitner S, et al. Late expression of p53 from a replicating adenovirus improves tumor cell killing and is more tumor cell specific than expression of the adenoviral death protein. Hum Gene Ther 2002; 13: 1859-1871.
11. Chen Y, DeWeese T, Dilley J, et al. CV706, a prostate cancer-specific adenovirus variant, in combination with radiotherapy produces synergistic antitumor efficacy without increasing toxicity. Cancer Res 2001; 61: 5453-5460.
12. Freytag SO, Paielli D, Wing M, et al. Efficacy and toxicity of replication-competent adenovirus-mediated double suicide gene therapy in combination with radiation therapy in an orthotopic mouse prostate cancer model. Int J Radiat Oncol Biol Phys 2002; 54: 873-885.
13. Dilley J, Reddy S, Ko D, et al. Oncolytic adenovirus CG7870 in combination with radiation demonstrates synergistic enhancements of antitumor efficacy without loss of specificity. Cancer Gene Ther 2005; 12: 715-722.
14. Toth K, Tarakanova, V, Doronin K, et al. Radiation increases the activity of oncolytic adenovirus cancer gene therapy vectors that overexpress the ADP (E3-11.6K) protein. Cancer Gene Ther 2003; 10: 193-200.
15. Lamfers ML, Grill J, Dirven CM, et al. Potential of the conditionally replicative adenovirus Ad5-Delta24RGD in the treatment of malignant gliomas and its enhanced effect with radiotherapy. Cancer Res 2002; 62: 5736-5742.
16. Geoerger B, Grill J, Opolon P, et al. Potentiation of radiation therapy by the oncolytic adenovirus dl1520 (ONYX-015) in human malignant glioma. xenografts. Br J Cancer 2003; 89: 577-584.
17. Badie B, Kramar MH, Lau R, et al. Adenovirus-mediated p53 gene delivery potentiates the radiation-induced growth inhibition of experimental brain tumors. J Neurooncol 1998; 37: 217-222.
18. Lang FF, Yung WK, Raju U, et al. Enhancement of radiosensitivity of wild-type p53 human glioma cells by adenovirus-mediated delivery of the p53 gene. J Neurosurg 1998; 89: 125-132.
19. Zolzer F, Streffer C. Quiescence in S-phase and G1 arrest induced by irradiation and/or hyperthermia in six human tumour cell lines of different p53 status. Int J Radiat Biol 2000; 76: 717-725.
20. Ishii N, Maier D, Merlo A, et al. Frequent co-alterations of TP53, p16/CDKN2A, p14ARF, PTEN tumor suppressor genes in human glioma cell lines. Brain Pathol 1999; 9: 469-479.
21. Ameyar M, Shatrov V, Bouquet C, et al. Adenovirus-mediated transfer of wild-type p53 gene sensitizes TNF resistant MCF7 derivatives to the cytotoxic effect of this cytokine: relationship with c-myc and Rb. Oncogene 1999; 18: 5464-5472.
22. Geoerger B, Grill J, Opolon P, et al. Oncolytic activity of the E1B-55 kDa-deleted adenovirus ONYX-015 is independent of cellular p53 status in human malignant glioma xenografts. Cancer Res 2002; 62: 764-772.
23. Vassal G, Terrier-Lacombe MJ, Lellouch-Tubiana A, et al. Tumorigenicity of cerebellar primitive neuro-ectodermal tumors in athymic mice correlates with poor prognosis in children. Int J Cancer 1996; 69: 146-151.
24. Badie B, Goh CS, Klaver J, et al. Combined radiation and p53 gene therapy of malignant glioma cells. Cancer Gene Ther 1999; 6: 155-162.
25. Shono T, Tofilon PJ, Schaefer TS, et al. Apoptosis induced by adenovirus-mediated p53 gene transfer in human glioma correlates with site-specific phosphorylation. Cancer Res 2002; 62: 1069-1076.
26. Chiocca EA, Abbed KM, Tatter S, et al. A phase I open-label, dose-escalation, multi-institutional trial of injection with an E1B-Attenuated adenovirus, ONYX-015, into the peritumoral region of recurrent malignant gliomas, in the adjuvant setting. Mol Ther 2004; 10: 958-966.
27. DeWeese TL, van der PH, Li S, et al. A phase I trial of CV706, a replication-competent, PSA selective oncolytic adenovirus, for the treatment of locally recurrent prostate cancer following radiation therapy. Cancer Res 2001; 61: 7464-7472.
28. Habib N, Salama H, Abd El Latif Abu Median, et al. Clinical trial of E1B-deleted adenovirus (dl1520) gene therapy for hepatocellular carcinoma. Cancer Gene Ther 2002; 9: 254-259.
29. Habib NA, Sarraf CE, Mitry RR, et al. E1B-deleted adenovirus (dl1520) gene therapy for patients with primary and secondary liver tumors. Hum Gene Ther 2001; 12: 219-226.
30. Freytag SO, Stricker H, Pegg J, et al. Phase I study of replication-competent adenovirus-mediated double-suicide gene therapy in combination with conventional-dose three-dimensional conformal radiation therapy for the treatment of newly diagnosed, intermediate- to high-risk prostate cancer. Cancer Res 2003; 63: 7497-7506.
31. Freytag SO, Khil M, Stricker H, et al. Phase I study of replication-competent adenovirus-mediated double suicide gene therapy for the treatment of locally recurrent prostate cancer. Cancer Res 2002; 62: 4968-4976.
32. Oosterhoff D, van Beusechem VW. Conditionally replicating adenoviruses as anticancer agents and ways to improve their efficacy. J Exp Ther Oncol 2004; 4: 37-57.
33. Khuri FR, Nemunaitis J, Ganly I, et al. A controlled trial of intraturnoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nat Med 2000; 6: 879-885.
34. Geoerger B, van Beusechem VW, Opolon P, et al. Expression of p53, or targeting towards EGFR, enhances the oncolytic potency of conditionally replicative adenovirus against neuroblastoma. J Gene Med 2005; 7: 584-594.
35. Steegenga WT, Riteco N, Jochemsen AG, et al. The large E1B protein together with the E4orf6 protein target p53 for active, degradation in adenovirus infected cells. Oncogene 1998; 16: 349-357.
36. Raki M, Kanerva A, Ristimaki A, et al. Combination of gemcitabine and Ad5/3-Delta24, a tropism modified conditionally replicating adenovirus, for the treatment of ovarian cancer. Gene Ther 2005; 12: 1198-1205.
37. Rogulski KR, Freytag SO, Zhang K, et al. In vivo antitumor activity of ONYX-015 is influenced by p53 status and is augmented by radiotherapy. Cancer Res 2000; 60: 1193-1196.
38. Helt AM, Galloway DA. Mechanisms by which DNA tumor virus oncoproteins target the Rb family of pocket proteins. Carcinogenesis 2003; 24: 159-169.
39. Akli S, Zhan S, Abdellatif M, et al. E1A can provoke G1 eidt that is refractory to p21 and independent of activating cdk2. Circ Res 1999; 85: 319-328.
40. Lamfers ML, Hemminki A. Multicellular tumor spheroids in gene therapy and oncolytic virus therapy. Curr Opin Mol Ther 2004; 6: 403-411.
41. Grill J, Lamfers ML, van Beusechem VW, et al. The organotypic multicellular spheroid is a relevant three-dimensional model to study adenovirus replication and penetration in human tumors in vitro. Mol Ther 2002; 6: 609-614.
42. Kambara H Saeki Y, Chiocca EA. Cyclophospharnide allows for in vivo dose reduction of a potent oncolytic virus. Cancer Res 2005; 65: 11255-11258.